Better Buy: Novavax, Inc. vs. Roche

Better Buy: Novavax, Inc. vs. Roche


Clinical-stage vaccine specialist Novavax, Inc. suffered one of the worst biotech beatdowns of 2016, but a win for its lead candidate in an ongoing late-stage trial could lead to market-crushing gains. Should investors take a chance with a risky little biotech that's still bleeding money, or play it safe with a company that's been profitable for years, but might face a slowdown going forward? Let's examine bull and bear arguments for each stock to see which is the better pick right now.



from Biotech News